secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLIGENIX, INC. (SNGX)
CIK:        0000812796
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001558370-25-011625
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Soligenix orphan drug designation for SGX945 in Behçet's Disease
---------------------------------------------------------------------------

- FDA orphan drug designation for dusquetide (SGX945) in Behçet's Disease based on Phase 2a results showing biological efficacy and safety.
- Designation provides 7 years U.S. market exclusivity upon FDA approval, plus NDA fee waiver, tax credits, and clinical trial grants.
- Behçet's Disease affects up to 18,000 in the U.S. and 1 million worldwide; current treatments have significant unmet need.
- CEO notes Phase 2a study demonstrated clinically meaningful improvements in oral aphthous ulcers in Behçet's patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/812796/000155837025011625/0001558370-25-011625-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/812796/000155837025011625/sngx-20250818x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011625

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer